Study of AN4035 for advanced cancers with RAS mutations and CEACAM5
Part of Cancer clinical trials.
This trial tests a new drug, AN4035, for people with advanced cancers that have certain RAS gene mutations and high levels of a protein called CEACAM5. The goal is to see if AN4035 can help when other treatments have stopped working or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your cancer must be advanced or metastatic and has progressed after standard treatments, or you have chosen not to take them
- Your tumor must have a specific RAS gene mutation (KRAS, NRAS, or HRAS) and high CEACAM5 protein levels
- You need to be in good physical health, able to do daily activities without major help (ECOG score 0 or 1)
- You must have at least one tumor that can be measured on scans, and you need to provide a tumor sample from a biopsy within the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Hear when a new RAS Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.